Alfuzosin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Alfuzosin
- Alfuzosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
Alfuzosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Alfuzosin is a selective α1-adrenergic receptor antagonist, primarily used to treat benign prostatic hyperplasia (BPH) and hypertension. The TxGNN model predicts it may be effective for Ambras Type Hypertrichosis Universalis Congenita — a rare genetic condition causing excessive whole-body hair growth — however, no clinical trials and no supporting publications exist for this direction, and the underlying mechanistic rationale is considered weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Benign Prostatic Hyperplasia (BPH) / Hypertension (no Singapore registration data available) |
| Predicted New Indication | Ambras Type Hypertrichosis Universalis Congenita |
| TxGNN Prediction Score | 99.999% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from this evidence pack. Based on known pharmacological information, Alfuzosin is a selective α1-adrenergic receptor antagonist (alpha-1 blocker). Its established efficacy in benign prostatic hyperplasia relies on relaxing smooth muscle in the prostate and bladder neck, thereby relieving urinary obstruction. It also has a role in hypertension management through peripheral vascular smooth muscle relaxation.
The proposed mechanistic bridge to hair disorders rests on the observation that α1-adrenergic receptors are expressed in the arrector pili muscles of hair follicles. Theoretically, blocking α1 signalling could influence the hair follicle cycle. However, Ambras type hypertrichosis universalis congenita is caused by mutations in the TRPS1 gene — a zinc-finger transcription factor governing hair follicle development — which has no established direct relationship with adrenergic signalling pathways. The TxGNN model's high confidence score (99.999%) most likely arises from indirect traversal paths within the knowledge graph (e.g., hair disorder nodes connecting through shared adrenergic-related intermediaries) rather than from a genuine therapeutic biology, and should be regarded as model noise.
A critical red flag further undermines this prediction: hypertrichosis (excessive hair growth) has been reported as an adverse effect of Alfuzosin in clinical use. This suggests that α1 blockade may actively promote rather than suppress hair growth, creating a direct pharmacological contradiction with the proposed repurposing rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Alfuzosin is currently not registered in Singapore. No marketing authorizations were found in the regulatory database.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial or published literature evidence supporting Alfuzosin for Ambras type hypertrichosis universalis congenita. The condition is driven by a specific genetic mutation (TRPS1) with no known mechanistic connection to α1-adrenergic blockade, and the paradox that hypertrichosis is itself a reported adverse effect of this drug makes the repurposing rationale logically inconsistent.
To proceed, the following would be needed:
- Verified MOA data from DrugBank confirming any hair follicle biology involvement
- Preclinical evidence (e.g., in vitro or animal model data) demonstrating that α1-adrenergic blockade influences TRPS1-associated hair growth pathways
- Resolution of the pharmacological paradox: Alfuzosin causes hypertrichosis as a side effect — any proposed mechanism for treating hypertrichosis must address this contradiction directly
- Singapore HSA package insert data to complete safety screening (currently blocking Step S1 safety assessment)
- If the broader TxGNN candidate list is being reviewed, note that allergic urticaria (rank 7) and persistent fetal circulation syndrome (rank 8) carry more mechanistically coherent rationales and are classified as "Research Question" rather than "Hold" — these may be more productive targets for hypothesis generation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.